Atlanta, GA (PRWEB) May 29, 2013
Syntermed, Inc. recently received clearance from the Food and Drug Administration regarding the newest update of NeuroQ 3.6, software used by nuclear medicine labs doing FDG-PET brain scans. NeuroQ 3.6(TM) is now FDA cleared with a 510K indication for the analysis of amyloid uptake levels in various regions of the brain.
The NeuroQ 3.6 program is designed to perform a quantitative analysis of amyloid imaging and FDG-PET brain scans using a standardized Region of Interest (ROI) method. This software program will analyze the distribution of FDG and amyloid PET tracers in individual scans, as well as the sometimes hard to detect differences between two PET scans on the same patient taken at different points in time. NeuroQ automatically calculates the values within pre-defined regions of the brain to assist with the final interpretation of the images by nuclear medicine specialists.
“NeuroQ is on a new frontier, breaking down traditional methods of brain scan interpretation so that physicians can achieve less variability in the final report used to evaluate patients with dementia,” said Michael Lee, CEO, Syntermed. This software program originated with the scientific expertise of Dan Silverman, MD, PhD, David Geffen School of Medicine at UCLA, Director, UCLA Brain Wellness Center, an international expert in imaging-assisted differential diagnosis of the many types of dementia including Alzheimer’s.
In related news, NeuroQ 3.6 will now be fully previewed at the upcoming Society of Nuclear Medicine and Molecular Imaging annual meeting June 8-10 in Vancouver, BC. Dr. Silverman will be presenting a NeuroPET preceptor training course entitled, “The Current State of Brain PET and Applications to the Diagnosis of Neurosurgical, Neurologic and Psychiatric Diseases.” Syntermed is providing the educational grant for the SNMMI training course.
“At Syntermed, we are dedicated to advancing the education of nuclear medicine specialists and technicians so that ultimately health care consumers will have greater access to more sites throughout the world offering advanced levels of care for brain cognitive issues. Our technology supports the current wave in medicine for intelligent software that provides decision support,” said Ken Van Train, President, Syntermed, Inc. “We are following Dr. Silverman’s lead to work diligently to support the training of many more physicians in a field where relatively few have his level of experience.”
The importance of Amyloid PET brain scans was underscored in a recent joint report by SNMMI and Alzheimers.org as (reported in The Journal of Dementia and Alzheimers, Jan. 2013).
Syntermed, Inc. is an Atlanta-based imaging and informatics software company that serves nuclear cardiology and nuclear medicine labs with its quantification and decision support software. Since 1999 Syntermed software has been utilized on SPECT and PET imaging systems. Today, the Emory Toolbox(TM), now in its fourth generation, is one of the most widely applied methods of cardiac imaging, used in nearly half of all nuclear medicine labs nationwide. For advanced phase analysis imaging studies of left ventricle dyssynchrony, Syntermed offers SyncTool(TM). For brain scan images using PET, Syntermed’s NeuroQ is the most widely used commercially quantitative solution in the world. All of Syntermed’s software is compatible with virtually any nuclear medicine workstation or PC/MAC that supports Microsoft® Windows® operating system. Syntermed Live enables physicians to access images and reports using computer access from a secure server at any time of the day.